These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

619 related articles for article (PubMed ID: 34739424)

  • 41. Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
    Hill BT; Rybicki LA; Urban TA; Lucena M; Jagadeesh D; Gerds AT; Dean RM; Sobecks RM; Pohlman B; Bolwell B; Kalaycio ME; Hamilton BK; Copelan EA; Majhail NS
    Biol Blood Marrow Transplant; 2020 Feb; 26(2):262-271. PubMed ID: 31610237
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Electroencephalogram abnormality and high-dose busulfan in conditioning regimens for stem cell transplantation.
    Kobayashi R; Watanabe N; Iguchi A; Cho Y; Yoshida M; Arioka H; Naito H; Shikano T; Ishikawa Y
    Bone Marrow Transplant; 1998 Feb; 21(3):217-20. PubMed ID: 9489642
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine.
    Kikuchi T; Mori T; Ohwada C; Onoda M; Shimizu H; Yokoyama H; Onizuka M; Koda Y; Kato J; Takeda Y; Hino Y; Mishina T; Sakaida E; Shono K; Nagao Y; Yokota A; Matsumoto K; Morita K; Okamoto S;
    Int J Hematol; 2021 Jan; 113(1):128-133. PubMed ID: 32886279
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.
    Nagler A; Rocha V; Labopin M; Unal A; Ben Othman T; Campos A; Volin L; Poire X; Aljurf M; Masszi T; Socie G; Sengelov H; Michallet M; Passweg J; Veelken H; Yakoub-Agha I; Shimoni A; Mohty M
    J Clin Oncol; 2013 Oct; 31(28):3549-56. PubMed ID: 23980086
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development and validation of a test dose strategy for once-daily i.v. busulfan: importance of fixed infusion rate dosing.
    Kangarloo SB; Naveed F; Ng ES; Chaudhry MA; Wu J; Bahlis NJ; Brown CB; Daly A; Duggan P; Geddes M; Quinlan D; Savoie ML; Shafey M; Stewart DA; Storek J; Yang M; Zacarias N; Yue P; Magliocco AM; Russell JA
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):295-301. PubMed ID: 21801704
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Modification of the Bu/Cy myeloablative regimen using daily parenteral busulfan: reduced toxicity without the need for pharmacokinetic monitoring.
    Mamlouk K; Saracino G; Berryman RB; Fay JW; Pineiro LA; Vance EA; White M; Sandler I; Agura ED
    Bone Marrow Transplant; 2005 Apr; 35(8):747-54. PubMed ID: 15750611
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies.
    Williams CB; Day SD; Reed MD; Copelan EA; Bechtel T; Leather HL; Wingard JR; Abbott BL; Abhyankar S; McGuirk JP
    Biol Blood Marrow Transplant; 2004 Sep; 10(9):614-23. PubMed ID: 15319773
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term salivary function after conditioning with busulfan, fractionated or single-dose TBI.
    Garming-Legert K; Remberger M; Ringdén O; Hassan M; Dahllöf G
    Oral Dis; 2011 Oct; 17(7):670-6. PubMed ID: 21718391
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results.
    Kebriaei P; Bassett R; Lyons G; Valdez B; Ledesma C; Rondon G; Oran B; Ciurea S; Alousi A; Popat U; Patel K; Ahmed S; Olson A; Bashir Q; Shah N; Jones R; Marin D; Rezvani K; Nieto Y; Khouri I; Qazilbash M; Hosing C; Shpall E; Champlin RE; Andersson BS
    Biol Blood Marrow Transplant; 2017 Feb; 23(2):285-292. PubMed ID: 27816651
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intravenous compared with oral busulfan as preparation for allogeneic hematopoietic progenitor cell transplantation for AML and MDS.
    Sobecks RM; Rybicki L; Yurch M; Kalaycio M; Dean R; Andresen S; Pohlman B; Duong H; Bolwell B; Copelan E
    Bone Marrow Transplant; 2012 May; 47(5):633-8. PubMed ID: 21874055
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Efficacy and toxicity of intravenous busulfan-based conditioning treatment before hAematopoietic stem cell transplantation in children: preliminary report].
    Styczyński J; Debski R; Krenska A; Wysocki M
    Med Wieku Rozwoj; 2008; 12(4 Pt 2):1098-104. PubMed ID: 19531833
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapeutic drug monitoring of busulfan in transplantation.
    Russell JA; Kangarloo SB
    Curr Pharm Des; 2008; 14(20):1936-49. PubMed ID: 18691105
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Total body irradiation and cyclophosphamide plus antithymocyte globulin regimen is well tolerated and promotes stable engraftment as a preparative regimen before T cell-replete haploidentical transplantation for acute leukemia.
    Fu H; Xu L; Liu D; Liu K; Zhang X; Chen H; Chen Y; Han W; Wang Y; Wang J; Wang F; Huang X
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1176-82. PubMed ID: 24747336
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapeutic drug monitoring of intravenous busulfan in Thai children undergoing hematopoietic stem cell transplantation: A pilot study.
    Jansing T; Sanpakit K; Tharnpanich T; Jiranantakan T; Niphandwongkorn V; Chindavijak B; Suansanae T
    Pediatr Hematol Oncol; 2021 May; 38(4):346-357. PubMed ID: 33656974
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS.
    Alatrash G; Kidwell KM; Thall PF; Di Stasi A; Chen J; Zope M; Crain AK; Champlin RE; Popat U; Shpall EJ; Jones RB; Andersson BS
    Bone Marrow Transplant; 2019 Aug; 54(8):1245-1253. PubMed ID: 30532055
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients.
    Yeh RF; Pawlikowski MA; Blough DK; McDonald GB; O'Donnell PV; Rezvani A; Deeg HJ; McCune JS
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):265-72. PubMed ID: 21736869
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Efficacy and toxicity of intravenous busulfan-based conditioning before allogeneic peripheral blood stem cell transplantation for leukemia].
    Tong XZ; Xu DR; Zou WY; Li J; Luo SK; Peng AH; Zhang GC; Zheng D
    Ai Zheng; 2007 Aug; 26(8):914-8. PubMed ID: 17697559
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study.
    Bunin N; Aplenc R; Kamani N; Shaw K; Cnaan A; Simms S
    Bone Marrow Transplant; 2003 Sep; 32(6):543-8. PubMed ID: 12953124
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies.
    Malard F; Cahu X; Clavert A; Brissot E; Chevallier P; Guillaume T; Delaunay J; Ayari S; Dubruille V; Mahe B; Gastinne T; Blin N; Harousseau JL; Moreau P; Miplied N; Le Gouill S; Mohty M
    Biol Blood Marrow Transplant; 2011 Nov; 17(11):1698-703. PubMed ID: 21601642
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phenytoin as seizure prophylaxis in hematopoietic stem cell transplantation with busulfan conditioning.
    Germeraad RS; Demandt AMP; Rouhl RPW
    Front Neurol; 2022; 13():928550. PubMed ID: 36071908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.